Intellia Therapeutics Inc buy Guggenheim
Start price
12.05.25
/
50%
€7.88
Target price
12.05.26
€40.09
Performance (%)
50.25%
End price
13.05.26
€11.84
Summary
This prediction ended on 13.05.26 with a price of €11.84. With a performance of 50.25% the BUY prediction by Guggenheim was a big success. Guggenheim has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Intellia Therapeutics Inc | -2.653% | -2.653% | 77.502% |
| iShares Core DAX® | -1.862% | 0.670% | 0.920% |
| iShares Nasdaq 100 | -3.322% | 4.989% | 33.716% |
| iShares Nikkei 225® | -2.299% | 6.129% | 52.955% |
| iShares S&P 500 | -1.313% | 3.399% | 24.674% |
Comments by Guggenheim for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Guggenheim from $55.00 to $45.00. They now have a "buy" rating on the stock.
Ratings data for NTLA provided by MarketBeat
In the thread Trading Intellia Therapeutics Inc
Die von Guggenheim gewählte maximale Laufzeit wurde überschritten